



CPN Operations Office
200 First Street SW
Rochester, MN 55905

cancerpreventionnetwork@mayo.edu

Date: June 6, 2016

To: Site pharmacists, study coordinators, and investigators

From: CPN Operations Office

Re: Shipment of Study Agent to Participating Organizations

The procedures for ordering and receiving study agent for MAY2013-02-01 "Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection" were revised after approval of protocol Version 12.0. The purpose of this memo is to provide the updated information. This will be inserted into the protocol with the next modification.

NCI, DCP-supplied agents may be requested by the Investigator (or their authorized designees) at each Organization. DCP guidelines require that the agent be shipped directly to the institution or site where the agent will be prepared and administered. DCP does not permit the transfer of agents between institutions (unless prior approval from DCP is obtained). DCP does not automatically ship agents; the site must make a request. Agents are requested by completing the DCP Clinical Drug Request form (NIH-986) (to include complete shipping contact information) and faxing or mailing the form to the DCP agent repository contractor:

**John Cookinham
MRIGlobal
DCP Repository
425 Volker Blvd.
Kansas City, MO 64110
Phone: 816-360-5369
FAX: 816-753-5359
Emergency Telephone: 816-360-3800**

Study agent can be ordered as soon your site is given "Drug Shipment Authorization" by DCP and the CPN Operations Office. The DCP Clinical Drug Request Form (NIH-986) is available on the CPN website at this location: <http://cancerpreventionnetwork.org/sc.shtml>

Materials and supplies for formulation and administration of the vaccine injection, including the Collectra electroporation device, will be shipped to each site upon receipt of Drug Shipment Authorization.